Annexon (ANNX) Non-Current Deffered Revenue (2019 - 2021)

Annexon (ANNX) posted quarterly Non-Current Deffered Revenue of $946000.0 for Q1 2021, down 9.56% quarter-over-quarter from $1.0 million in Q4 2020.

Annexon (ANNX) Non-Current Deffered Revenue (2019 - 2021) Analysis & Trends

Annexon's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $946000.0 for Q1 2021.

In Q1 2021, Non-Current Deffered Revenue changed N/A year-over-year to $946000.0; the TTM figure through Mar 2021 stood at $946000.0 (changed N/A YoY), while the FY2020 annual figure was $1.0 million, down 27.21% from the prior year.
Non-Current Deffered Revenue for Q1 2021 stood at $946000.0, down from $1.0 million in the prior quarter.
The five-year high for Non-Current Deffered Revenue was $1.4 million in Q4 2019, with the low at $946000.0 in Q1 2021.
The 3-year median for Non-Current Deffered Revenue is $1.1 million (2020), against an average of $1.2 million.
Peak annual rise in Non-Current Deffered Revenue reached 27.21% in 2020, while the deepest fall reached 27.21% in 2020.
Annexon's Non-Current Deffered Revenue stood at $1.4 million in 2019, then retreated by 27.21% to $1.0 million in 2020, then dropped by 9.56% to $946000.0 in 2021.
Business Quant data shows ANNX's Non-Current Deffered Revenue at $946000.0 in Q1 2021, $1.0 million in Q4 2020, and $1.1 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	220.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Annexon	1.00 Bn	1.00 Bn	-	-

Download Data